RCT-2100 is under clinical development by Recode Therapeutics and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

The Business Journal has the list of the Massachusetts biotech companies that raised the largest venture capital rounds in the last year. Meet the most-capitalized companies of 2024.

Energy bill payers have been promised more protections and better customer service as part of plans to reform the regulator Ofgem. The watchdog could get new consumer-facing powers including ...

Gunnar Esiason isn't like most hockey players -- his ability to complete a shift often depended on how his cystic fibrosis was affecting him that day. Throughout his journey with CF, hockey became ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

Alyftrek combines vanzacaftor, tezacaftor and deutivacaftor and is the fifth cystic fibrosis transmembrane conductance regulator (CFTR) modulator from Vertex. The FDA approval covers patients who ...

Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments, but both therapies come with boxed warnings for potential ...

BERN: Switzerland's financial regulator was ineffective in tackling the scandals at Credit Suisse, where executive mismanagement scuppered the bank and nearly triggered a global financial crisis ...

It is the first once-daily treatment for cystic fibrosis transmembrane conductance regulator (CFTR) modulator, Vertex said. Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval.